172 related articles for article (PubMed ID: 32564984)
1. [Evolution and treatment of storm cytoquine syndrome associated to SARS-CoV-2 infection among octogenarians].
Callejas Rubio JL; Aomar Millán I; Moreno Higueras M; Muñoz Medina L; López López M; Ceballos Torres Á
Rev Esp Geriatr Gerontol; 2020; 55(5):286-288. PubMed ID: 32564984
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of corticoid pulses in patients with cytokine storm syndrome induced by SARS-CoV-2 infection.
Callejas Rubio JL; Luna Del Castillo JD; de la Hera Fernández J; Guirao Arrabal E; Colmenero Ruiz M; Ortego Centeno N
Med Clin (Barc); 2020 Aug; 155(4):159-161. PubMed ID: 32532461
[TBL] [Abstract][Full Text] [Related]
3. Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study.
Ramiro S; Mostard RLM; Magro-Checa C; van Dongen CMP; Dormans T; Buijs J; Gronenschild M; de Kruif MD; van Haren EHJ; van Kraaij T; Leers MPG; Peeters R; Wong DR; Landewé RBM
Ann Rheum Dis; 2020 Sep; 79(9):1143-1151. PubMed ID: 32719045
[TBL] [Abstract][Full Text] [Related]
4. Early identification of COVID-19 cytokine storm and treatment with anakinra or tocilizumab.
Langer-Gould A; Smith JB; Gonzales EG; Castillo RD; Figueroa JG; Ramanathan A; Li BH; Gould MK
Int J Infect Dis; 2020 Oct; 99():291-297. PubMed ID: 32768693
[TBL] [Abstract][Full Text] [Related]
5. Storm, typhoon, cyclone or hurricane in patients with COVID-19? Beware of the same storm that has a different origin.
Alunno A; Carubbi F; Rodríguez-Carrio J
RMD Open; 2020 May; 6(1):. PubMed ID: 32423970
[TBL] [Abstract][Full Text] [Related]
6. Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: Results from a single Italian Centre study on tocilizumab versus standard of care.
Quartuccio L; Sonaglia A; McGonagle D; Fabris M; Peghin M; Pecori D; De Monte A; Bove T; Curcio F; Bassi F; De Vita S; Tascini C
J Clin Virol; 2020 Aug; 129():104444. PubMed ID: 32570043
[TBL] [Abstract][Full Text] [Related]
7. Predictive factors of mortality in patients treated with tocilizumab for acute respiratory distress syndrome related to coronavirus disease 2019 (COVID-19).
Lohse A; Klopfenstein T; Balblanc JC; Royer PY; Bossert M; Gendrin V; Charpentier A; Bozgan AM; Badie J; Bourgoin C; Contreras R; Mazurier I; Conrozier T; Zayet S
Microbes Infect; 2020 Oct; 22(9):500-503. PubMed ID: 32574789
[TBL] [Abstract][Full Text] [Related]
8. SARS-CoV-2 infection in immunocompromised patients: humoral versus cell-mediated immunity.
Wei J; Zhao J; Han M; Meng F; Zhou J
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32727811
[TBL] [Abstract][Full Text] [Related]
9. Tocilizumab for Hemophagocytic Syndrome in a Kidney Transplant Recipient With COVID-19.
Faguer S; Del Bello A; Abravanel F; Nicolau-Travers ML; Kamar N
Ann Intern Med; 2020 Sep; 173(6):501-503. PubMed ID: 32432518
[No Abstract] [Full Text] [Related]
10. Itolizumab, an anti-CD6 monoclonal antibody, as a potential treatment for COVID-19 complications.
Loganathan S; Athalye SN; Joshi SR
Expert Opin Biol Ther; 2020 Sep; 20(9):1025-1031. PubMed ID: 32700604
[TBL] [Abstract][Full Text] [Related]
11. Cytokine Storm Drugs Move from CAR T to COVID-19.
Cancer Discov; 2020 Jul; 10(7):OF8. PubMed ID: 32371479
[TBL] [Abstract][Full Text] [Related]
12. COVID-19, Mast Cells, Cytokine Storm, Psychological Stress, and Neuroinflammation.
Kempuraj D; Selvakumar GP; Ahmed ME; Raikwar SP; Thangavel R; Khan A; Zaheer SA; Iyer SS; Burton C; James D; Zaheer A
Neuroscientist; 2020; 26(5-6):402-414. PubMed ID: 32684080
[TBL] [Abstract][Full Text] [Related]
13. Hemophagocytic lymphohistiocytosis in a patient with COVID-19 treated with tocilizumab: a case report.
Tholin B; Hauge MT; Aukrust P; Fehrle L; Tvedt TH
J Med Case Rep; 2020 Oct; 14(1):187. PubMed ID: 33054818
[TBL] [Abstract][Full Text] [Related]
14. Immunologic Features in Coronavirus Disease 2019: Functional Exhaustion of T Cells and Cytokine Storm.
Mahmoudi S; Rezaei M; Mansouri N; Marjani M; Mansouri D
J Clin Immunol; 2020 Oct; 40(7):974-976. PubMed ID: 32648027
[No Abstract] [Full Text] [Related]
15. Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up: A retrospective cohort study.
Moreno-Pérez O; Andres M; Leon-Ramirez JM; Sánchez-Payá J; Rodríguez JC; Sánchez R; García-Sevila R; Boix V; Gil J; Merino E
J Autoimmun; 2020 Nov; 114():102523. PubMed ID: 32690352
[TBL] [Abstract][Full Text] [Related]
16. The Combined Use of Tocilizumab and Hemoadsorption in a Patient with SARS-COV-2-19-Associated Pneumonia: A Case Report.
Berlot G; Tomasini A; Roman Pognuz E; Randino A; Chiella F; La Fata C; Piva M; Amato P; di Maso V; Bianco F; Gerini U; Tomietto P; Trenti T
Nephron; 2020; 144(9):459-462. PubMed ID: 32694244
[TBL] [Abstract][Full Text] [Related]
17. The Management of Cytokine Storm in COVID-19.
Rumende CM; Susanto EC; Sitorus TP
Acta Med Indones; 2020 Jul; 52(3):306-313. PubMed ID: 33020343
[TBL] [Abstract][Full Text] [Related]
18. Evidence for possible association of vitamin D status with cytokine storm and unregulated inflammation in COVID-19 patients.
Daneshkhah A; Agrawal V; Eshein A; Subramanian H; Roy HK; Backman V
Aging Clin Exp Res; 2020 Oct; 32(10):2141-2158. PubMed ID: 32876941
[TBL] [Abstract][Full Text] [Related]
19. A complex COVID-19 case with rheumatoid arthritis treated with tocilizumab.
Cai S; Sun W; Li M; Dong L
Clin Rheumatol; 2020 Sep; 39(9):2797-2802. PubMed ID: 32562070
[TBL] [Abstract][Full Text] [Related]
20. Comparative Survival Analysis of Immunomodulatory Therapy for Coronavirus Disease 2019 Cytokine Storm.
Narain S; Stefanov DG; Chau AS; Weber AG; Marder G; Kaplan B; Malhotra P; Bloom O; Liu A; Lesser ML; Hajizadeh N;
Chest; 2021 Mar; 159(3):933-948. PubMed ID: 33075378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
